Cytodyn Inc (CYDY)

[JJAAMMAANN]

CytoDyn (CYDY) Given a $2.00 Price Target at HC Wainwright

Xavier Javi
CytoDyn logoCytoDyn (OTCMKTS:CYDY) received a $2.00 target price from HC Wainwright in a report issued on Tuesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 220.00% from the company’s current price.

Shares of CytoDyn (CYDY) opened at $0.63 on Tuesday. CytoDyn has a 12 month low of $0.46 and a 12 month high of $0.84. The company has a market capitalization of $108.67, a price-to-earnings ratio of -2.72 and a beta of 0.83.

About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.